Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly and Novo Nordisk — the dominant players in obesity drug development — each submitted a new weight-loss drug to the ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

Lilly has now submitted a new drug application (NDA) for orforglipron to the FDA for use in adults with obesity.

Good news for people on GLP-1 therapy who hate needles: Trial data out this week shows that an experimental pill developed by ...

Orforglipron helped keep weight down when used after initial therapy with an injectable, a new treatment strategy that could ...

Eli Lilly seeks FDA approval for orforglipron, a once-daily pill shown in trials to help maintain weight loss after stopping ...

Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the ...

Lilly’s Attain-Maintain Phase III results show that the oral GLP-1 orforglipron can effectively preserve weight loss after injectable therapy, positioning it as a potential long-term maintenance ...

Eli Lilly reports Phase 3 data showing oral obesity drug orforglipron maintained weight loss after Wegovy or Zepbound, beating placebo.

Eli Lilly (LLY) stock is in focus as the company posts late-stage trial data to indicate that its obesity pill orforglipron ...

The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many ...